Literature DB >> 12931134

Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin.

H Takahashi1, H Echizen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12931134     DOI： 10.1038/sj.tpj.6500182

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  21 in total

Review 1.  Pharmacokinetic variability of long-acting stimulants in the treatment of children and adults with attention-deficit hyperactivity disorder.

Authors:  James C Ermer; Ben A Adeyi; Michael L Pucci
Journal:  CNS Drugs       Date:  2010-12       Impact factor: 5.749

Review 2.  Pharmacogenetics of warfarin: challenges and opportunities.

Authors:  Ming Ta Michael Lee; Teri E Klein
Journal:  J Hum Genet       Date:  2013-05-09       Impact factor: 3.172

Review 3.  Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese population.

Authors:  Wen-ying Shu; Jia-li Li; Xue-ding Wang; Min Huang
Journal:  Acta Pharmacol Sin       Date:  2015-04-20       Impact factor: 6.150

4.  A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9.

Authors:  Soo-Youn Lee; June Soo Kim; Jong-Won Kim
Journal:  Yonsei Med J       Date:  2005-12-31       Impact factor: 2.759

5.  VKORC1 pharmacogenomics summary.

Authors:  Ryan P Owen; Li Gong; Hersh Sagreiya; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

Review 6.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.

Authors:  Anne-Charlotte Castellan; Michel Tod; François Gueyffier; Mélanie Audars; Fredéric Cambriels; Behrouz Kassaï; Patrice Nony
Journal:  Clin Pharmacokinet       Date:  2013-03       Impact factor: 6.447

Review 8.  Warfarin Pharmacogenetics: New Life for an Old Drug.

Authors:  Ming-Shien Wen; Ming Ta Michael Lee
Journal:  Acta Cardiol Sin       Date:  2013-05       Impact factor: 2.672

9.  A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Authors:  Fumihiko Takeuchi; Ralph McGinnis; Stephane Bourgeois; Chris Barnes; Niclas Eriksson; Nicole Soranzo; Pamela Whittaker; Venkatesh Ranganath; Vasudev Kumanduri; William McLaren; Lennart Holm; Jonatan Lindh; Anders Rane; Mia Wadelius; Panos Deloukas
Journal:  PLoS Genet       Date:  2009-03-20       Impact factor: 5.917

10.  A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.

Authors:  Soo Youn Lee; Myung Hyun Nam; June Soo Kim; Jong Won Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.